Temozolomide tmz
Temozolomide (TMZ) is a pharmaceutical product manufactured by Merck Group. It functions as a chemotherapeutic agent used in the treatment of certain types of brain cancers. TMZ is a synthetic alkylating agent that interferes with DNA replication, leading to cell death in rapidly dividing cells.
Lab products found in correlation
69 protocols using temozolomide tmz
Brain Cancer Chip Drug Combination Protocol
Functionalization of Temozolomide for Theranostics
Cytotoxicity Assay for Anticancer Drugs
Antibody-based targeting of Sph-1P in cancer cells
Preparation of TMZ, ANGPTL4, and Inhibitor Solutions
Inhibiting NF-κB and Inducing Apoptosis
CXCR4, miR-182, and PPP1R1C modulate temozolomide sensitivity
Cytotoxicity Assay with MCL and TMZ
Glioma and Astrocyte Cell Cultures Protocol
For sphere cultures, LN18 glioma cells were seeded at a low density (1500 cells/cm2) on non-adherent plates and cultured in DMEM/F-12 GlutaMAX™ supplemented with 2% B27, 20 ng/mL rhuman bFGF, 20 ng/mL rhuman EGF, 0.0002% heparin and antibiotics (for details see
Antibody-based Assay for ASAH1
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!